Details of the Drug
General Information of Drug (ID: DMPEV2W)
Drug Name |
(R)-3-Prop-2-ynylamino-indan-5-ol
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
5-Hydroxy-N-propargyl-1(R)-aminoindan; 5-HYDROXY-N-PROPARGYL-1(R)-AMINOINDAN; CHEMBL371428; 6-hydroxy-n-propargyl-1(r)-aminoindan; (3R)-3-(PROP-2-YNYLAMINO)INDAN-5-OL; (3R)-3-(prop-2-yn-1-ylamino)-2,3-dihydro-1H-inden-5-ol; R-HPAI; AC1NRD0T; Aminoindan deriv (R)39u; SCHEMBL4188273; BDBM10799; 1H-Inden-5-ol, 2,3-dihydro-3-(2-propyn-1-ylamino)-, (3R)-; DB04307; 479206-03-6; 5-Hydroxy-N-Propargyl-1(R)-Aminoindan
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure | ||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 187.24 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 1.5 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | |||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References